Protein-Encapsulated Doxorubicin Reduces Cardiotoxicity in hiPSC-Cardiomyocytes and Cardiac Spheroids While Maintaining Anticancer Efficacy

The authors used human induced pluripotent stem cell-derived (hiPSC) cardiomyocytes, endothelial cells, cardiac fibroblasts, multi-lineage cardiac spheroids, patient-specific hiPSCs, and multiple human cancer cell lines to compare the anticancer efficacy and reduced cardiotoxicity of single protein encapsulated doxorubicin, to standard unformulated doxorubicin.